Gastrointestinal contrast agent developer E-Z-EM of Westbury, NY, this month appointed David Wills as general manager for its U.K. subsidiary, E-Z-EM Ltd. of London. Wills plans to focus on bolstering the company’s share in the U.K. barium sulfate
Gastrointestinal contrast agent developer E-Z-EM of Westbury, NY, this month appointed David Wills as general manager for its U.K. subsidiary, E-Z-EM Ltd. of London. Wills plans to focus on bolstering the companys share in the U.K. barium sulfate contrast market. He comes to E-Z-EM from Medtronic U.K. Ltd., where he served as business development manager for that firms peripheral vascular division. Wills brings 16 years of medical device sales experience to his new post.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.